In this Application Note, discover how the Protein Sciences group at Merck & Co. builds developability profiles for their monoclonal antibody variants.  

Get an in-depth explanation of the experiments they set up to obtain parameters that help them decide which candidates have the best potential to reach the market, and how they validated that the data they obtained to do this work matched up with previous profiles.

You’ll learn about:

• Why it was important for Merck to build developability profiles from biophysical stability attributes of their candidates
• Which parameters they measured to create these profiles
• Why a combinatorial approach was valuable to their workflow
• How they validated that the addition of DLS-derived parameters did not compromise their previous nanoDSF-derived data

Brought to you by